Chinese biotech developing antibody-drug conjugates and biologics for autoimmune disease and cancer.
Chinese biotech developing antibody-drug conjugates and biologics for autoimmune disease and cancer.
Earns from sales of its two lead drugs in China, mostly to hospitals, and from licensing: overseas rights to disitamab vedotin were licensed to Seagen, now part of Pfizer, bringing upfront and milestone payments. This is its Shanghai STAR market listing; the same company also lists in Hong Kong.
In one line: A Chinese Seagen/Horizon Therapeutics hybrid.
Moat: narrow (IP / patents, scale). Proprietary ADC and dual-target biologic platform with first-in-class assets in China.
Headquarters: Yantai, China · Founded: 2008 · Employees: 3,048
Size RemeGen (688331.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $6.28B, the 372nd largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥86.70 on 18 Nov 2026.
Performance Over six months the shares fell 24.4%, against -4.5% for the median peer and -20.0% for the China market (cap-weighted) — 5th lowest of 20 in its peer set.
Growth Revenue grew 272.3% over the last twelve months (peer median +12.5%); the operating margin is 60.9% (peer median 15.8%).
Valuation It trades at 10.8× forward earnings against a peer median of 25.1× (2nd cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +303%, so the hurdle is -302 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 95.7 points above its cost of capital (12.3% WACC).
Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥8.29B | CN¥3.25B | CN¥1.71B | CN¥1.08B | CN¥772M |
| Revenue growth | — | +90% | +58% | +40% | — |
| Gross profit | CN¥7.83B | CN¥2.62B | CN¥1.18B | CN¥661M | CN¥363M |
| EBITDA | n/a | CN¥451M | -CN¥1.16B | -CN¥1.34B | -CN¥1.02B |
| Net income | CN¥6.53B | CN¥710M | -CN¥1.47B | -CN¥1.51B | -CN¥999M |
| Free cash flow | CN¥3.80B | -CN¥144M | -CN¥1.51B | -CN¥2.35B | -CN¥2.00B |
| Capital expenditure | CN¥133M | CN¥200M | CN¥265M | CN¥853M | CN¥753M |
| Total debt | CN¥292M | CN¥2.20B | CN¥2.67B | CN¥1.27B | CN¥278M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| RemeGen 688331.SS | $6.28B | -24% | +272% | 61% | 10.8× | 1.1% |
| Shanghai Junshi Biosciences 1877.HK | $3.49B | -38% | +36% | -14% | n/a | n/a |
| Innovent Biologics 1801.HK | $18.9B | +4% | +43% | 17% | 52.3× | 11.6% |
| Sichuan Kelun-Biotech Biopharmaceutical 6990.HK | $13.0B | -1% | +44% | -38% | 1,176.1× | 55.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688331.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -13.3% | -0.3% | 6th lowest of 21 |
| 6-month return | -24.4% | -4.5% | 5th lowest of 20 |
| Distance from 52-week high | -45.1% | -20.4% | 5th lowest of 21 |
| Revenue growth (TTM) | +272.3% | +12.5% | highest of 18 |
| Operating margin | 60.9% | 15.8% | highest of 19 |
| Forward P/E | 10.8× | 25.1× | 2nd cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 1.1% | 6.2% | 5th least demanding of 10 |
| Growth delivered (Del g) | +303.3% | +10.7% | highest of 10 |
| Hurdle (Req g minus delivered) | -302.3 pp | -7.7 pp | least demanding of 10 |
| ROIC minus cost of capital | +95.7 pp | +1.9 pp | highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| RemeGen 688331.SS | China | $6.28B | -24% | +272% | 61% | 10.8× | 1.1% | +303.3% |
| Biocon BIOCON.NS | India | $6.31B | -15% | +6% | 8% | 61.3× | n/a | n/a |
| Belite Bio, Inc. ADR BLTE | United States | $6.41B | +9% | n/a | n/a | n/a | n/a | n/a |
| Samsung Epis 0126Z0.KS | South Korea | $6.49B | -31% | n/a | 12% | 23.8× | n/a | n/a |
| Oruka Therapeutics ORKA | United States | $6.49B | +58% | n/a | n/a | n/a | n/a | n/a |
| Mirum Pharmaceuticals MIRM | United States | $6.04B | -5% | +42% | -21% | n/a | n/a | n/a |
| Apotex Health APTX.TO | Canada | $6.56B | n/a | +4% | 32% | 19.3× | -11.9% | +4.2% |
| Supernus Pharmaceuticals SUPN | United States | $6.02B | -41% | +16% | 45% | 8.0× | 6.2% | +13.9% |
| China Resources Sanjiu Medical & Pharmaceutical 000999.SZ | China | $6.59B | +6% | +4% | 14% | 13.2× | -6.2% | +18.4% |
| Ligand Pharmaceuticals LGND | United States | $5.98B | +37% | +1% | 14% | 27.3× | 57.7% | +7.5% |
| Alkem Laboratories ALKEM.NS | India | $6.69B | -5% | +13% | 17% | 27.3× | 25.0% | +10.7% |
| Huadong Medicine 000963.SZ | China | $6.69B | -18% | +2% | 9% | 12.5× | -3.9% | +5.3% |
| Abbott India ABBOTINDIA.NS | India | $5.80B | -8% | +7% | 28% | 31.1× | 8.0% | +10.0% |
| Gland Pharma GLAND.NS | India | $5.71B | +44% | +22% | 21% | 39.3× | 20.2% | +13.3% |
| Akeso 9926.HK | Hong Kong | $7.01B | -48% | +42% | -25% | n/a | n/a | n/a |
| Bachem BANB.SW | Switzerland | $7.06B | 0% | +5% | 19% | 32.4× | n/a | n/a |
| Gan & Lee Pharmaceuticals 603087.SS | China | $5.59B | +11% | +14% | 20% | 25.8× | n/a | n/a |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $7.10B | +17% | +24% | 17% | 24.4× | n/a | n/a |
| ImmunityBio IBRX | United States | $7.13B | -17% | +121% | -150% | n/a | n/a | n/a |
| Cytokinetics CYTK | United States | $7.15B | -35% | +30% | -625% | n/a | n/a | n/a |
| ONO Pharmaceutical 4528.T | Japan | $7.33B | -2% | -2% | 22% | 15.3× | -6.8% | +10.8% |